Ernexa Therapeutics Inc. filed a Form 8-K on November 19, 2026, disclosing that its Board of Directors approved a Consulting Agreement Addendum on November 14, 2026, adding monthly cash compensation of $5,000 for Mark J. Keeley, who provides Chief Financial Officer services to the company.
Key Highlights
- Addendum effective date: The Consulting Agreement Addendum became effective November 9, 2026.
- Board approval date: The Board of Directors approved the Addendum on November 14, 2026, upon recommendation of the Compensation Committee.
- New cash compensation: Mark J. Keeley will receive $5,000 per month, payable on the last day of each month, prorated for November 2026.
- Underlying agreement: The Addendum supplements the original Consulting Agreement dated August 10, 2026, between the company and Mr. Keeley.
- Existing compensation retained: All other terms of the Consulting Agreement, including Mr. Keeley's share-based compensation, remain in full force and effect.
- Role: Mr. Keeley provides Chief Financial Officer services to Ernexa Therapeutics Inc. under the consulting arrangement.
Board Approves Cash Supplement to CFO Consulting Arrangement at Ernexa Therapeutics
According to the filing, the Board of Directors of Ernexa Therapeutics Inc. (NASDAQ:ERNA), a Delaware corporation headquartered at 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141, approved a Consulting Agreement Addendum on November 14, 2026, acting on the recommendation of its Compensation Committee. The Addendum, effective November 9, 2026, modifies the existing Consulting Agreement dated August 10, 2026, between the company and Mark J. Keeley.
The filing disclosed that, pursuant to the Addendum, Mr. Keeley's existing share-based compensation under the Consulting Agreement "is supplemented with monthly cash compensation in the amount of $5,000, payable on the last day of each month and prorated for the month of November 2026." The company stated that all other terms of the original Consulting Agreement remain in full force and effect. Mr. Keeley serves the company in a Chief Financial Officer capacity under this consulting arrangement.
The company noted in the filing that the description of the Addendum "does not purport to be complete and is qualified in its entirety by reference to the full text of the Addendum," which was filed as Exhibit 10.1 to the Current Report. The Form 8-K was signed by Sanjeev Luther, President and Chief Executive Officer, on November 19, 2026. Common Stock Purchase Warrants of the company trade on NASDAQ under the symbol ERNAW.
What Was Disclosed
Ernexa Therapeutics disclosed a November 14, 2026 Board-approved addendum to its CFO consulting arrangement, adding $5,000 in monthly cash compensation for Mark J. Keeley, effective November 9, 2026, while all prior consulting terms remain unchanged.




Please wait processing your request...